syy891013

Rising need for innovative law enforcement solutions. AXON long

Long
syy891013 Updated   
NASDAQ:AXON   Axon Enterprise, Inc.
Quantitative Analysis
• Earnings growth positive and above sector average
• Stock P/E on a premium to sector and positive
• Global Law Enforcement Software Market size is expected to grow from USD 16.4 billion in 2023 to USD 25.6 billion by 2028, according to a new report by Marketsand Markets.
• Increased rates and the changing nature of crime are major drivers for the rise in the need for innovative law enforcement solutions and services.
• Increase in US gun violence in recent years. Axon aims to cut gun-related deaths between police and the public by 50% in the next decade.

Business
• Strong demand for Axon Cloud SaaS services, Axon Fleet 3, and Taser 7
• New major products innovations – Taser 10 platform, body camera, Axon Body 4
• Axon Body 4 is currently being trialed by several agencies in the U.S. and will begin shipping in the second half of 2023.
• TASER 10 was unveiled in January 2023 and the company expects order volume to grow throughout 2023.
• Continuing to shift an increasing amount of business to a subscription model.

KPIs
• Full year 2023 revenue expected to be between $1.44 billion to $1.46 billion, reflecting approximately 22% year over year growth at the midpoint.
• Adjusted EBITDA margin of 20% in 2023.
• Expect stock-based compensation expense to be approximately $141 million for the full year.
• Expect 2023 CapEx to be in the range of $50 million to $65 million.
• Total company future contracted revenue expected to recognized between 15% to 25% of $4.8 billion over the next twelve months.

Catalysts
• Strong 2023 Q2 earnings
• Axon Body 4 and TASER 10 sales
• Investment in Cellebrite DI Ltd (“CLBT”)

Trade
Trade might take longer than expected to work. Targeting August 2023 earnings for movement.
Trade closed: stop reached:
Stop loss hit. However. still confident with the fundamentals. Will wait for a bullish price action to enter again.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.